A Phase III, Open-label, Single Arm, Prospective, Multicenter Study to Assess Efficacy and Safety of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Adult Patients With Chronic Immune Thrombocytopenia (ITP)
Latest Information Update: 23 Jul 2025
At a glance
- Drugs Immune globulin (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Registrational; Therapeutic Use
- Acronyms ITP
- Sponsors Kedrion
Most Recent Events
- 23 Jul 2025 New trial record